23andMe Holding Past Earnings Performance
Past criteria checks 0/6
23andMe Holding's earnings have been declining at an average annual rate of -24%, while the Healthcare industry saw earnings growing at 5.6% annually. Revenues have been declining at an average rate of 7.6% per year.
Key information
-24.0%
Earnings growth rate
50.3%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | -7.6% |
| Return on equity | -353.7% |
| Net Margin | -303.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation
Apr 16
Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%
Mar 02We're Keeping An Eye On 23andMe Holding's (NASDAQ:ME) Cash Burn Rate
Jul 1323andMe Holding Co. (NASDAQ:ME) Investors Are Less Pessimistic Than Expected
Jun 1523andMe: Disappointing Results Could Mean Potential Acquisition Target
Sep 2723andMe: Treacherous Path To Profitability
Aug 2623andMe drops 8% as CFO resigns
Aug 1923andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target
Aug 1123andMe Q1 2023 Earnings Preview
Aug 0723andMe: Holiday Miracles Not Enough, Growth Path Too Expensive
Jun 1523andMe: A Genetics Innovator Positioned For Growth
Feb 19Need To Know: Analysts Are Much More Bullish On 23andMe Holding Co. (NASDAQ:ME) Revenues
Feb 1823andMe: No Surprises With Recent Earnings, But Long-Term Story Remains Positive
Nov 2123andMe Stock: Continued Drug-Development Progress Can Deliver Long-Term Gains
Oct 03Companies Like 23andMe Holding (NASDAQ:ME) Are In A Position To Invest In Growth
Sep 1723andMe: New Therapeutic Pipeline And PGS Product Growth Catalyzed By +$696M In SPAC Funding
Jul 19Revenue & Expenses Breakdown
How 23andMe Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 220 | -667 | 183 | 205 |
| 31 Dec 23 | 248 | -522 | 235 | 219 |
| 30 Sep 23 | 270 | -336 | 236 | 235 |
| 30 Jun 23 | 296 | -327 | 246 | 233 |
| 31 Mar 23 | 299 | -312 | 226 | 223 |
| 31 Dec 22 | 308 | -317 | 233 | 212 |
| 30 Sep 22 | 298 | -315 | 237 | 205 |
| 30 Jun 22 | 277 | -265 | 213 | 197 |
| 31 Mar 22 | 272 | -217 | 188 | 189 |
| 31 Dec 21 | 260 | -215 | 188 | 185 |
| 30 Sep 21 | 259 | -170 | 153 | 176 |
| 30 Jun 21 | 255 | -190 | 146 | 170 |
| 31 Mar 21 | 244 | -184 | 142 | 160 |
| 31 Mar 20 | 305 | -251 | 170 | 181 |
| 31 Mar 19 | 441 | -184 | 241 | 141 |
Quality Earnings: ME is currently unprofitable.
Growing Profit Margin: ME is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ME is unprofitable, and losses have increased over the past 5 years at a rate of 24% per year.
Accelerating Growth: Unable to compare ME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ME is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (15.1%).
Return on Equity
High ROE: ME has a negative Return on Equity (-353.65%), as it is currently unprofitable.